BURLINGAME, Calif., May 14 /PRNewswire-FirstCall/ -- Valentis, Inc. announces the following Webcast:
What: Valentis’ Third Quarter Fiscal 2004 Financial Results and Corporate Update When: May 17 @ 4:30 p.m. EDT Where: http://www.firstcallevents.com/service/ajwz406851711gf12.html How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Joe Markey, +1-650-697-1900, or jmarkey@valentis.com
If you are unable to participate during the live webcast, the call will be archived at http://www.valentis.com .
Valentis is creating innovative cardiovascular therapeutics. The company begins its product development at the stage of a validated target and applies its expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs. Specifically, we combine our proprietary delivery technologies with genes to create novel therapeutic products. Deltavasc(TM), the Company’s lead product is based on the Del-1 angiogenesis gene, formulated with a Valentis PINC(TM) proprietary polymer delivery system. The Company has three proprietary delivery technologies for the development of novel therapeutics: PINC(TM) polymer delivery systems for gene delivery, GeneSwitch(R) for control of gene expression and DNA Vax(TM) polymer delivery systems for DNA vaccines.
(Minimum Requirements to listen to broadcast:
The Windows Media Player software, downloadable free from http://www.microsoft.com/windows/windowsmedia/EN/default.asp and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webcastsupport@tfprn.com .)
Audio: http://www.firstcallevents.com/service/ajwz406851711gf12.htmlValentis Inc
CONTACT: Joe Markey of Valentis, +1-650-697-1900, orjmarkey@valentis.com
Web site: http://www.valentis.com/